Template talk:PPAR modulators

This template does not require a rating on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Pharmacology This template is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles Chemicals This template is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this template or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles Medicine This template is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles Molecular Biology: MCB This template is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles This template is supported by the Molecular and Cell Biology task force.

One in-vitro study determined that ibuprofen at 500μM induced lipogenesis, the main hallmark of PPARγ activation, 100μM had no effect; 500μM translates to an oral dose in the ballpark of 3,100mg—is this effect relevant enough to include in this template?

Indomethacin with 80μM as the lipogenic dose translates to doses far exceeding 1,000mg—another super-therapeutic dose.

In that study, the method for determining agonist efficacy is questionable—it does not assess PPARγ with its RXRα coactivator, hence ibuprofen could in fact be a weak partial agonist when paired with RXRα—which is why I'm ignoring it.

Pleased to hear additional information, but at this point I'm very tempted to remove this potentially misinformed item. Insect.eate (talk) 00:35, 10 October 2024 (UTC)[reply]

Correction: Ibuprofen is sometimes administered in doses of 800mg 4 times daily, quite possibly enough for PPARγ effects to manifest. I don't know what to do here, input from others is appreciated—I'm not sure whether items in templates are supposed to be clinically relevant examples, or whether tentative in-vitro evidence is enough for inclusion.

If it's the latter, NSAIDs like indomethacin and naproxen should possibly be included alongside ibuprofen. Insect.eate (talk) 05:44, 12 October 2024 (UTC)[reply]